This inbred strain is derived from the outbred strain ICR. It may be useful in therapeutic drug testing and genetic analysis of carcinogen-induced colon cancer.
Rosemary W. Elliott, Roswell Park Cancer Inst.
This inbred strain is derived from the outbred stock ICR. ICR/HaJ may serve as a general purpose strain and is known for susceptibility to induced colon cancer. In contrast to resistant C57BL/6HaJ (009123), 100% of ICR/HaJ mice develop colon tumors and adenocarcinomas by 24 weeks following subcutaneous injection of 1,2-dimethylhydrazine (DMH). ICR/HaJ carries the MHC haplotype H2g7 and may be used as a control for NOD/ShiLtJ (Stock #001976). Mice do not develop insulitis or diabetes. Like ICR, this inbred is highly prolific. This strain may be useful in therapeutic drug testing, genetic analysis of carcinogen-induced colon cancer and as control for NOD/ShiLtJ.
This inbred strain was developed from the HA(ICR) outbred stock brought to the Roswell Park Cancer Institute by Dr. Hauschka in 1954. HA(ICR) originated from a Swiss Webster stock purchased from J. C. Landis in 1947 and was maintained by Dr. Hauschka at the Institute for Cancer Research in Philadelphia. HA(ICR) was selected for reproductive vigor (fecundity) and is one of the most prolific of the outbred strains. ICR/Ha has been maintained by sibling matings at Roswell Park for more than 30 years. Dr. Rosemary Elliott donated this strain to the Repository in 2009.
ICR/HaJ mice are susceptible to eye inflammation, therefore nestlets are not recommended as bedding material.
When using the ICR/HaJ mouse strain in a publication, please include JAX stock #009122 in your Materials and Methods section.